Q2 2026 Global Health Ltd Earnings Call Transcript
Key Points
- Global Health Ltd (BOM:543654) commenced operations at its sixth facility, Medanta Noida, which is a 550-bed state-of-the-art hospital, marking a significant expansion in their network.
- The company announced plans to establish a 400-plus bed super specialty hospital in Guwahati, expanding their reach to the northeast region.
- The Mumbai project received additional FSI approval, allowing expansion from a 500 to a 750-bed super specialty hospital, indicating growth potential in Western India.
- Consolidated total income for Q2 FY2026 was INR11,189 million, a 15% increase compared to the same quarter last year, showcasing strong financial growth.
- Profit after tax for the period was INR1,584 million, reflecting a robust year-on-year growth of 21%, indicating improved profitability.
- Medanta Noida reported an EBITDA loss of INR197 million in its first month of operations, reflecting initial ramp-up challenges.
- The EBITDA margin, including Noida, was 23.3%, down from 25.3% in the same quarter last year, indicating pressure on profitability.
- The mature hospitals' EBITDA growth was only 2.2% year on year, impacted by additional manpower costs and lower incidence of vector-borne diseases.
- The company faces challenges with payment delays from CGHS and ECHS, with realization periods extending up to 9 months, affecting cash flow.
- There is ongoing competition for clinical talent, particularly in the NCR market, which could impact staffing and operational efficiency.
Ladies and gentlemen, good day and welcome to Global Health Medanta Hospital's Q2 FY26 earnings conference call hosted by IIFL Capital. (Operator Instructions) I now have the conference open to Mr. Rahul Giovanni from IIFL Capital. Thank you and over to you, Mr. Giovanni.
Hi, good afternoon, everyone. This is Rahul from IIFL Capital. On behalf of IIFL, I welcome you all to the second quarter, earnings conference call of Medanta. From Medanta we have with us today Dr. Naresh Trehan, Chairman and Managing Director; Mr. Pankaj Sahani, Group Chief Executive Officer and Director; Mr. Yogesh Kumar Gupta, Chief Financial Officer; and Mr. Ravi, Gothwal, Head Investor Relations, over to you, sir, for your opening comments.
Good afternoon. And thank you for joining us today for Medanta's Q2 FY26 earnings conference call. I hope all of you have had the chance to review the results and presentations that were released
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
